4:45 PM ET
8-K/A
M&A Deal
Glucotrack M&A Deal with Lokahi Therapeutics Inc.
Glucotrack, Inc. filed an amended 8-K to provide updated pro forma financial statements regarding its completed acquisition of Lokahi Therapeutics Inc. The update specifically reflects the impact of a 1-for-15 reverse stock split that became effective on August 28, 2026. Following the merger, Lokahi became a direct wholly owned subsidiary of Glucotrack.
- Counterparty
- Lokahi Therapeutics Inc.